Company Filing History:
Years Active: 2006
Title: Ana Mendez Zunzunegui: Innovator in Vaccine Development
Introduction
Ana Mendez Zunzunegui is a prominent inventor located in Pontevedra, Spain. With her innovative approach to vaccine development, she has contributed significantly to the field of immunology. Mendez Zunzunegui holds one patent that focuses on using recombinant defective viral genomes to create vaccines, showcasing her expertise in biotechnological advancements.
Latest Patents
Ana’s notable patent is titled "Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines." This invention involves vectors that incorporate a recombinant defective viral genome, which expresses at least one antigen. This antigen is designed to induce systemic and secretory immune responses or to generate antibodies that provide protection against various infectious agents. The viral genome is characterized by specific structural features, including the 3' and 5' ends with viral replicase recognition signals, along with internal deletions. These vectors are particularly beneficial for creating mono- and polyvalent vaccines against infectious agents affecting different animal species, including pigs, dogs, and cats.
Career Highlights
Ana Mendez Zunzunegui works at Cyanamid Ibérica, S.A., a company dedicated to advancements in pharmaceutical and vaccine development. Her work in this company highlights her commitment to improving animal health through innovative technologies.
Collaborations
Throughout her career, Ana has collaborated with esteemed colleagues such as Luis Enjuanes Sanchez and Juan Plana Duran. These partnerships have undoubtedly enhanced the impact of her research in vaccine formulation and development.
Conclusion
Ana Mendez Zunzunegui stands out as a vital contributor to the field of veterinary immunology. Her patent for recombinant viral genome vectors represents a significant step forward in vaccine technology, with the potential to safeguard the health of various animal species. Through her work at Cyanamid Ibérica and her collaborations, Ana continues to push the boundaries of innovation in the pharmaceutical industry.